inflammation of the septum, turbinates and lateral wall, with mucoid secretions. Biopsies of the right middle turbinate were consistent with acute inflammation. There was no evidence of squamous dysplasia, carcinoma or lymphoma. Several weeks later, repeat cultures of purulent nasal secretions grew normal flora. His nasal symptoms persisted, and deeper, more generous biopsies were taken. The right septal biopsy featured apoptotic/ dyskeratotic keratinocytes and some vacuolization of the epithelium, suggestive of acute GVHD (Figures 1a and b) . Staining was negative for fungal organisms and cytomegalovirus. He was started on topical budesonide 0.5 mg/ml twice daily. Within a month, he noted some improvement. PET/CT scan showed unchanged soft tissue thickening within the nasal cavity and no active lymphoma. He is now using nasal cyclosporine spray with continuing but manageable symptoms. He has never had any other systemic findings of GVHD, and no evidence of chronic 
This case involves severe, late-onset acute GVHD affecting nasal and sinus mucosa. This is a very difficult diagnosis to establish given that the non-specific constellation of symptoms and concurrent histopathology has not previously been well described. His nasal symptoms started shortly after discontinuation of tacrolimus. In the nasal mucosal biopsy of the patient, although apoptotic change within the mucosa was present, the prominent feature was acute and chronic inflammation. The differential diagnosis included infections and lymphoma. However, biopsies and cultures were negative for pathogenic organisms over more than a year. Moreover, neither appropriate antimicrobial therapy nor IVIG replacement improved his symptoms. Biopsies also did not show evidence of lymphoma, and ofatumumab therapy did not improve PET avidity in nasal mucosa, in contrast to that observed in the retroperitoneal mass. His symptoms have significantly improved with GVHD therapy consisting of local steroids and cyclosporine. With regard to the possibility of reaction to mediations (nasal steroids or decongestants), the patient was clinically symptomatic prior to initiation of these treatments, and he did not have a clinical response to them. He was off the decongestants at the time of biopsy. Therefore, taken together, we believe that this case represents a rare-severe nasal GVHD and recommend that GVHD be part of the differential diagnosis in patients with sinus symptoms post alloHCT.
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